| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mogroside II-A is a plant metabolite and is functionally related to mogroside I-A1. Its primary "target" is the sweet taste receptor, although it is also being studied for other potential biological activities. As a natural product, it does not have a well-defined pharmacological target like a specific enzyme.
|
|---|---|
| ln Vitro |
In vitro, Mogroside II-A is studied for its potential biological activities, such as its antioxidant, anti-inflammatory, or other properties. However, as a natural sweetener, its primary activity is its interaction with the sweet taste receptor. It is used as a research tool to study the metabolism and bioactivity of mogrosides.
|
| ln Vivo |
In vivo, Mogroside II-A, like other mogrosides, is not significantly metabolized and is primarily excreted unchanged. Its main activity is its sweet taste, but it is also being investigated for its potential health benefits, such as its effects on glucose metabolism and inflammation. More research is needed to confirm these activities.
|
| Enzyme Assay |
In vitro assays for Mogroside II-A typically involve studying its biological activities in cell culture. For example, its antioxidant activity can be measured using assays like DPPH or ABTS radical scavenging. Its effects on glucose uptake or inflammatory markers can be studied in appropriate cell lines.
|
| Cell Assay |
Cellular assays are performed using relevant cell lines to study specific activities. For example, the compound's effects on glucose metabolism can be studied in hepatic or muscle cells. Its anti-inflammatory effects can be studied in immune cells. Cells are treated with the compound, and various endpoints are measured.
|
| Animal Protocol |
Mogroside II-A is not typically administered as a drug in animal studies. However, it can be used in studies to understand the metabolism and health effects of monk fruit extracts. In such studies, animals are fed a diet containing the compound, and its effects on various physiological parameters are monitored.
|
| ADME/Pharmacokinetics |
Mogroside II-A has a molecular weight of 801.01 g/mol and a chemical formula of C42H72O14. As a large, highly glycosylated molecule, its oral bioavailability is expected to be very low. It is poorly absorbed and is primarily metabolized by the gut microbiota. Most of the ingested compound is excreted unchanged in the feces.
|
| Toxicity/Toxicokinetics |
Mogroside II-A is generally recognized as safe as it is a component of monk fruit, a widely consumed food. It has a very low toxicity profile. High doses are not associated with significant adverse effects.
|
| References | |
| Additional Infomation |
Mogroside IIA is a mogroside and also a β-D-glucoside. It is a plant metabolite and is functionally related to mogroside I-A1.
Mogroside II-A is a natural product isolated from Siraitia grosvenorii. It is one of the several mogrosides that contribute to the intense sweetness of monk fruit. It is primarily used as a research tool to study the chemistry, metabolism, and potential health benefits of these natural sweeteners. |
| Molecular Formula |
C42H72O14
|
|---|---|
| Molecular Weight |
801.01
|
| Exact Mass |
800.492
|
| CAS # |
1613527-65-3
|
| PubChem CID |
138911437
|
| Appearance |
White to off-white solid powder
|
| Density |
1.33±0.1 g/cm3(Predicted)
|
| Boiling Point |
919.5±65.0 °C(Predicted)
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
56
|
| Complexity |
1410
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@H]3CC[C@@]4([C@@]3(C[C@H]([C@@]5([C@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O)C)O)C)C
|
| InChi Key |
NZDCGZOHJTWGOX-KZQQMABOSA-N
|
| InChi Code |
InChI=1S/C42H72O14/c1-20(21-15-16-40(6)26-12-10-22-23(11-13-27(45)38(22,2)3)42(26,8)28(46)17-41(21,40)7)9-14-29(39(4,5)52)55-37-35(33(50)31(48)25(19-44)54-37)56-36-34(51)32(49)30(47)24(18-43)53-36/h10,20-21,23-37,43-52H,9,11-19H2,1-8H3/t20-,21-,23-,24-,25-,26+,27+,28-,29-,30-,31-,32+,33+,34-,35-,36+,37+,40+,41-,42+/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5S,6R)-2-[(3R,6R)-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-3,11-dihydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-hydroxy-2-methylheptan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~124.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2484 mL | 6.2421 mL | 12.4842 mL | |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
